Bevacizumab in Advanced Cervical Cancer


The FDA approved bevacizumab in combination with paclitaxel plus cisplatin or topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer in August 2014, based on the phase III GOG 240 study. Although both regimens are approved, the more commonly administered regimen is cisplatin and paclitaxel, notes Bradley J. Monk, MD.

In the GOG 240 trial, the addition of bevacizumab, an anti-VEGF monoclonal antibody, to chemotherapy in recurrent, persistent, or metastatic cervical cancer improved overall survival (OS) by 3.9 months. The median OS was 16.8 months with bevacizumab compared with 12.9 months for chemotherapy alone (HR = 0.74; 98% CI, 0.58-0.94; P = .0132).

The study also revealed an association between gastrointestinal perforations, vaginal fistulas, and bevacizumab therapy. While gastrointestinal perforations are generally lethal, says Monk, vaginal fistulas may not be lethal but are catastrophic, commenting that is important for clinicians to weigh the 8% vaginal fistula rate against the nearly 4-month improvement in OS.

Related Videos
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Alexey Danilov, MD, PhD,
Chul Kim, MD, MPH
Robert DeBernardo, MD, section head, Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic
Michael Hagensee, MD, PhD, Louisiana State University Health, New Orleans School of Medicine
Susan Marie Lang, MD
Gabriella Smith, MD
Sarah Crafton, MD